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Introduction
Rett syndrome (RTT [MIM #312750]) was discovered
when two girls who exhibited the same unusual behav-
iors happened to be seated next to each other in the
waiting room of Andreas Rett, a Viennese pediatrician.
It took 130 years after this discovery to determine the
genetic basis of RTT, largely because the disease is pri-
marily sporadic in nature and because familial cases are
scarce. The discovery that mutations in methyl-
CpG–binding protein 2 (MECP2) cause RTT and other
neurodevelopmental disorders has called attention to the




RTT affects ∼1/15,000 females worldwide (Hagberg
1985; Kerr and Stephenson 1985; Kozinetz et al. 1993).
The classic form of the disease, found almost exclusively
in females, follows a distinct developmental course that
Andreas Rett described as “both tragic and fascinating”
(Rett 1986). Affected girls are born healthy, appear to
develop normally until age 6–18 mo, and achieve the
expected motor, language, and social milestones (Hag-
berg et al. 1983). Their neurological development is then
arrested and begins regressing in a predictable pattern
comprising roughly four stages (Hagberg and Witt-En-
gerstrom 1986). During Stage I (age 6–18 mo), girls
cease to acquire new skills; they display decelerating
head growth and autistic features such as emotional
withdrawal and diminished eye contact. In Stage II (age
1–4 years), affected children lose learned skills such as
speech and purposeful hand use. They develop irregular
breathing patterns, truncal and gait ataxia/apraxia, and
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stereotypical hand wringing; about half the girls also
develop seizures. There is some stabilization of the dis-
ease during Stage III (age 4–7 years), because loss of
skills can continue only to a point. During this stage,
girls may learn to communicate preferences using eye
pointing. They still have gross cognitive and motor im-
pairments and commonly experience epileptic episodes.
Seizures become less frequent during Stage IV (age 5–15
years and older), but motor deterioration continues. Hy-
poactivity, especially among those who cannot walk,
contributes to the frequent development of scoliosis,
which can cause the girls to be confined to wheelchairs
(Hagberg and Witt-Engerstrom 1986).
Other features are associated with RTT but are not
diagnostic. For example, patients with RTT are generally
small for their age (Holm 1986). Some have suggested
that this growth retardation is due to poor self-feeding
abilities and reduced caloric intake (Thommessen et al.
1992), but others have found it to be independent of
diet (Rice and Haas 1988). Many patients display an
abnormally long QTc interval (Sekul et al. 1994; Guideri
et al. 1999). Although females with RTT often live well
into adulthood, the mortality rate is 1.2% per year, with
about 1/4 of these deaths described as sudden and un-
explained (Kerr et al. 1997). Incidents of sudden death
have been postulated to result from breathing dysfunc-
tion and cardiac abnormalities (Sekul et al. 1994; Gui-
deri et al. 1999). Finally, patients with RTT often have
signs of autonomic dysfunction such as constipation and
cold or pale extremities (Hagberg et al. 1983; Naidu et
al. 1986).
In addition to classic RTT (summarized in table 1),
five distinct categories of atypical cases have been delin-
eated on the basis of clinical criteria (Hagberg and Skjel-
dal 1994). These variants have some, but not all, di-
agnostic features of RTT and can be milder or more
severe. Milder variants include the forme fruste (“worn-
down form”), the late regression variant, and the pre-
served speech variant (Hagberg and Witt-Engerstrom
1986; Zappella 1992; Hagberg and Skjeldal 1994). The
more severe forms are the congenital form and the early-
seizure-onset variant (Hanefeld 1985; Goutieres and Ai-
cardi 1986; Hagberg and Skjeldal 1994).
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Table 1
Phenotypes Associated with MECP2 Mutations in Human Females
CHARACTERISTIC
PHENOTYPE FOR
Classic RTTa Mild RTT Variantsb Severe RTT Variantsc
Age at onset Onset between 6–18 mo Later onset Congenital onset
Head/body size Small head, body May have small head, body Small head, body
Seizures Seizures Early seizure onset
Speech Loss of speech Speech is preserved
Motor function Motor deficiencies Usually ambulatory Hypotonia, motor deficiencies
Hand use Stereotypical hand motions Retain hand use
Social Interactions Autistic features
Intelligence Mental retardation Mild or no mental retardation Mental retardation
Spinal curvature Scoliosis and/or kyphosis Scoliosis and/or kyphosis
Respiration Breathing dysfunction Breathing dysfunction
a Null alleles or severe inactivating mutations, balanced XCI.
b Hypomorphic alleles (late truncations) with balanced XCI or null alleles with favorably skewed XCI. (Very late
truncations and some missense mutations, such as A140V and Q406X, result in no phenotype in females even when
XCI is balanced. These same mutations do, however, produce phenotypes in males.)
c Null alleles or severe inactivating mutations, possibly due to unfavorably skewed XCI.
Neurophysiology
The electroencephalogram (EEG) is typically normal
until 3 years of age (Verma et al. 1986; Glaze et al.
1987). After this period, the background activity re-
mains normal, but repetitive high-amplitude spike-and-
wave discharges (focal, multifocal, or generalized) are
seen. Later, the background activity becomes abnormally
slow (Verma et al. 1986). After 10 years of age, the
background activity shows additional slowing, but, con-
sistent with the reduction in seizures during the final
stage of the disease, the EEG discharges are reduced in
frequency, amplitude, and duration (Niedermeyer et al.
1986; Verma et al. 1986).
Breathing appears to be normal during sleep, but pe-
riods of irregular breathing (hyperventilation followed
by periods of apnea) often occur during wakefulness,
particularly when patients are under emotional or phys-
ical stress (Lugaresi et al. 1985; Cirignotta et al. 1986;
Southall et al. 1988). Because the respiratory abnor-
malities in RTT are restricted to the wakeful state, it is
thought that the voluntary system for regulating
breathing is affected rather than the autonomic system,
which controls respiration during non–rapid-eye-move-
ment sleep (Lugaresi et al. 1985).
Neuroimaging
Volumetric magnetic resonance imaging studies show
an overall decrease in brain volume, affecting gray mat-
ter more than white matter, but reveal no evidence of
neurodegeneration (Reiss et al. 1993). The caudate nu-
cleus and frontal cortex show the largest reduction in
volume (Reiss et al. 1993; Subramaniam et al. 1997).
The volume of white matter does increase with age, how-
ever, suggesting that myelinization progresses normally
(Reiss et al. 1993).
As measured by single photon emission–computed to-
mography, global cerebral blood flow (a measure of neu-
ronal metabolism) is 22% lower in patients with RTT
(Nielsen et al. 1990). At a regional level, blood flow in
the frontal, parietal, and temporal regions is significantly
lower than in control individuals, whereas that in the
occipital and sensorimotor areas is normal (Nielsen et
al. 1990; Lappalainen et al. 1997). Because the blood
flow pattern in the brains of patients with RTT resembles
the pattern of normal infants before age 6 mo, it has
been proposed that blood flow pattern reflects devel-
opmental arrest (Nielsen et al. 1990).
Neuropathology
In spite of a deteriorating clinical course and diverse
neurological features, the brain pathology in RTT re-
veals only subtle abnormalities. As one might expect
from both imaging studies and the clinical deceleration
in head growth, postmortem studies consistently find
that brains of patients with classic RTT weigh
14%–34% less than those of control subjects’ brains
(Jellinger and Seitelberger 1986). To control for the fact
that patients with RTT often have a reduced body size,
organ weights have been compared with those of normal
individuals of the same height to show that there is a
selective decrease in the size of the brain (Armstrong et
al. 1999).
RTT was first thought to be a neurodegenerative dis-
ease because of the developmental regression, but the
majority of neuropathological findings argue against this
and indicate that it is a disorder of arrested neuronal
development (Armstrong 2001). Impaired neuronal de-
velopment was initially suggested by the observation
that the dendrites of pyramidal neurons of the frontal
and motor cortex were reduced in length and complexity
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(Armstrong 1992; Armstrong et al. 1995). Three-di-
mensional confocal microscopy studies confirmed these
findings and also revealed a reduction in the number of
dendritic spines (Belichenko et al. 1994). Other studies
showed that neurons of the cerebral cortex, basal gan-
glia, thalamus, hippocampus, amygdala, and substantia
nigra were smaller and more densely packed than in
control subjects (Bauman et al. 1995). The observation
of reduced pigmentation in the substantia nigra (Jellinger
and Seitelberger 1986) also suggests impaired neuronal
development, since melanin pigment normally accu-
mulates in these neurons from the 5th postnatal wk of
development until age 12–15 years (Fenichel and Ba-
zelon 1968; Spence and Gilles 1971).
A number of molecular changes are consistent with
this neuropathology. The dendritic alterations observed
in postmortem tissue could be related to reductions in
the levels of microtubule-associated protein 2 (an im-
portant cytoskeletal component of neuronal dendrites),
substance P (a neuropeptide that has been shown to
stimulate neurite extension in cultured neuroblastoma
cells), and prostaglandin endoperoxide H synthase-2
(the rate-limiting enzyme in prostanoid biosynthesis that
localizes to dendritic spines and marks mature neurons)
(Whitty et al. 1993; Kaufmann et al. 1995, 1996, 1997;
Matsuishi et al. 1997; Deguchi et al. 2000). These path-
ological observations support the conclusion that, al-
though glial development occurs normally, neuronal
development is hindered. Whether the molecular alter-
ations are a cause or a result of the abnormal devel-
opment has not been determined.
Genetic Aspects of RTT
Mapping of the Mutated Gene
The mode of inheritance of RTT was difficult to de-
termine, because only ∼1% of RTT cases are familial
and because affected individuals rarely reproduce (Scha-
nen 1999). Nevertheless, the virtual absence of affected
males and the presence of families with affected half-
sisters suggested an X-linked dominant inheritance pat-
tern with male lethality (Hagberg et al. 1983; Killian
1986). Consistent with an X-linked mutation, analysis
of the available families revealed that inheritance
through maternal lineages was common (Zoghbi 1988).
Furthermore, in families where the mother was an ob-
ligate carrier (e.g., families with affected half-sisters or
aunt-niece pairs), X-chromosome inactivation (XCI)
studies often revealed skewed XCI patterns in the un-
affected mother (Zoghbi et al. 1990; Schanen et al.
1997). Some substantiation for the male-lethality aspect
of the X-linked hypothesis was provided by males, born
into families with RTT, who displayed neonatal enceph-
alopathy with hypotonia, seizures, apnea, and infantile
death (Ruch et al. 1989; Schanen et al. 1997, 1998).
The identification of males who harbored an extra X-
chromosome (47,XXY) and bore features identical to
those of RTT was also compatible with X-linked inher-
itance (Vorsanova et al. 1996).
Conventional genomewide linkage analysis was not
feasible in RTT because of the rarity of familial cases
and the limited vertical transmission. A focused exclu-
sion-mapping approach on the basis of the hypothesis
of an X-linked mutation (Archidiacono et al. 1991; El-
lison et al. 1992; Curtis et al. 1993; Schanen et al. 1997;
Schanen and Francke 1998; Sirianni et al. 1998) cul-
minated in the exclusion of most of the X-chromosome,
leaving only the region distal to Xq27.3. Conventional
linkage analysis using the few available families with
recurrent RTT revealed linkage to markers in this region
with a peak LOD score of 2.9 (Sirianni et al. 1998; Webb
et al. 1998; Xiang et al. 1998). A number of genes within
Xq27.3-qter were analyzed for mutations in patients
with RTT because of their known expression or function
in the central nervous system (Wan and Francke 1998;
Amir et al. 2000a; Xiang et al. 2000), but mutations
were finally identified in the methyl-CpG-binding pro-
tein 2 gene (MECP2 [MIM 300005]), a widely expressed
transcriptional repressor (Amir et al. 1999).MECP2 had
previously been mapped to human Xq28 and was found
to be subject to XCI (Quaderi et al. 1994; Adler et al.
1995; D’Esposito et al. 1996; Vilain et al. 1996).
MECP2 Mutations in Classic RTT
Data from many laboratories have demonstrated that
mutations in MECP2 are the primary cause of RTT,
because mutations have been identified in 70%–90% of
sporadic cases and ∼50% of familial cases (Shahbazian
and Zoghbi 2001). Only the coding region has been
thoroughly analyzed, however, so mutations in regula-
tory elements could account for those cases in which no
mutation has been identified. Consistent with the prom-
inence of CrT transition mutations at 5′-CG-3′ (CpG)
sites in other disease genes, presumably resulting from
spontaneous deamination of methylated cytosine resi-
dues (Cooper and Youssoufian 1988), almost 70% of
the reported mutations result from this transition at only
eight different CpG dinucleotides within the MECP2
gene (Lee et al. 2001).
MECP2 Mutations in RTT Variants
As noted above, there are several variants on the clas-
sic RTT phenotype, which itself is complex and variable.
One of the first questions to be addressed after the dis-
covery of MECP2 mutations was whether these RTT
variants are truly alternate forms of the same entity.
Findings indicate that a majority of females with the
preserved speech variant do have mutations in MECP2
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Table 2
Phenotypic Categories for MECP2 Mutations in Human Males
Allele Type Phenotype
Null (early trucating mutations and some missense mutations) (1) Neonatal encephalopathy, severe hypotonia, seizures, apnea, and
infantile death; or (2) RTT-like features with 47,XXY karyotype
or somatic mosaicism
Hypomorphic (late truncations and some missense mutations) (1) Mental retardation, no delayed development of language but
macrocephaly, tremors, ataxia, hypoactivity, and seizures; (2)
childhood-onset schizophrenia with loss of language; or (3)
manic-depressive psychosis, pyramidal signs, and macro-
orchidism
(De Bona et al. 2000; Yamashita et al. 2001; Zappella
et al. 2001). Mutations have also been identified in a
fraction (20%–40%) of patients with other forms of the
disease, including the forme fruste and congenital var-
iants (Buyse et al. 2000; Cheadle et al. 2000; Huppke
et al. 2000; Bourdon et al. 2001; Inui et al. 2001; Nielsen
et al. 2001) (see table 1). The lower percentage of iden-
tified MECP2 mutations in patients with atypical RTT
could indicate the presence of genocopying mutations
or could suggest that RTT variants are more frequently
associated with (as-yet-unidentified) mutations in regu-
latory elements of MECP2 than the classic form of the
disease.
Origin of MECP2 mutations
The prediction that most mutations occur de novo
(Comings 1986) has been verified with multiple obser-
vations that the mutations found in sporadic cases are
not present in somatic cells from either parent (Amir et
al. 1999; Wan et al. 1999; Bienvenu et al. 2000; Buyse
et al. 2000; Erlandson et al. 2001; Monros et al. 2001;
Nicolao et al. 2001). Since mutations on the paternal
X-chromosome would be inherited by daughters but not
sons, some have proposed a high paternal:maternal ratio
of de novo mutations to explain the low incidence of
affected males (Thomas 1996). This hypothesis is, in
fact, correct: haplotype analysis has shown that 195%
of MECP2 mutations originate on the paternal chro-
mosome (Girard et al. 2001; Trappe et al. 2001). A high
ratio of male:female germ-cell mutations is not unique
to MECP2; it has been documented for a number of
human disease genes (Crow 2000). It is also known that
almost 40% of the mutations responsible for various
diseases occur at CpG sites (Cooper and Youssoufian
1988). The higher levels of methylation in male germ
cells at early stages of gametogenesis, in addition to the
greater number of mitotic divisions in the male germline,
could explain sex-specific mutation patterns (Driscoll
and Migeon 1990; El-Maarri et al. 1998).
Effect of XCI
Skewed XCI patterns had been postulated to explain
the occurrence of unaffected carrier females in families
with recurrent RTT (Zoghbi et al. 1990). In support of
this idea, skewed XCI (presumably favoring inactivation
of the mutant allele) has been observed in females who
carry RTT-causing mutations but are asymptomatic or
suffer from only mild learning disability (Wan et al.
1999; Amir et al. 2000b; Bienvenu et al. 2000; Villard
et al. 2000; Hoffbuhr et al. 2001). Although it seems
likely that cells expressing mutant MECP2 would have
some growth disadvantage and be selected against, this
appears not to be the case: the same mutation is present
in the carrier females and their affected daughters. In
fact, the majority of affected females have a balanced
pattern of XCI, both in peripheral blood and brain tissue
(Amir et al. 2000b; Shahbazian et al. 2002b). Therefore,
the skewed XCI pattern in carrier females is probably
due to chance.
RTT Mutations in Males
Mutation analysis has also shed light on the question
of whether the boys who developed neonatal encepha-
lopathy and died within 1–2 years of birth suffered the
consequences ofMECP2 mutations (table 2). Indeed, the
same mutations that are present in their sisters with clas-
sic RTT proved to be the cause of disease in these boys
(Wan et al. 1999; Villard et al. 2000; Hoffbuhr et al.
2001; Geerdink et al. 2002; Zeev et al. 2002). Males
bearing a mild MECP2 mutation that would likely pro-
duce a very mild phenotype in girls (i.e., late truncating
mutations and some missense mutations) can survive the
neonatal period, but they develop severe mental retar-
dation associated with motor abnormalities (table 2). In
contrast to these cases, there are several instances of
males with RTT-causing MECP2 mutations that have
developed an RTT phenotype. In these cases, some other
modifier is present, such as somatic mosaicism for the
mutation or a partial or complete Klinefelter (47,XXY)
karyotype (Clayton-Smith et al. 2000; Armstrong et al.
2001; Hoffbuhr et al. 2001; Leonard et al. 2001;
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Schwartzman et al. 2001; Vorsanova et al. 2001; Topcu
et al. 2002). In these situations, the effect of an MECP2
mutation in a male is mitigated in the same way that it
is in a female, that is, by only a fraction of cells expressing
the mutant MECP2 allele.
Genotype-Phenotype Correlation
Several groups have conducted genotype-phenotype
correlation studies to determine whether different types
of mutations in MECP2 can account for the variability
of clinical features in patients with RTT; these studies
have yielded inconsistent results. Two groups found that
truncating mutations lead to a more severe overall phe-
notype than missense mutations (Cheadle et al. 2000;
Monros et al. 2001), and one of these studies further
showed that late truncations correlate with a less severe
outcome than early truncations (Cheadle et al. 2000).
In 18 females with the preserved speech variant, all the
mutations were either missense or late truncations, fur-
ther supporting the notion that these types of mutations
have milder consequences than the early truncations seen
in classic RTT (Zappella et al. 2001). Several other stud-
ies, however, have found no significant correlation be-
tween the mutation type and the overall severity of clin-
ical features (Amir et al. 2000b; Bienvenu et al. 2000;
Huppke et al. 2000; Giunti et al. 2001; Yamada et al.
2001; Chae et al. 2002). This discordance likely results
from the fact that the pattern of XCI can influence the
phenotypic outcome of mutations in females.
In males, the confounding effect of XCI is absent, and
the correlation between the type of mutation and the
phenotypic outcome is clearer. As mentioned, MECP2
mutations that cause classic RTT in females lead to ne-
onatal encephalopathy and infantile death in males un-
less the mutations are mitigated by somatic mosaicism
or a Klinefelter phenotype (table 2). In contrast, other
mutations in MECP2, which are not known to cause
RTT in females, have been found in males manifesting
various features, some of which are seen in RTT. For
example, a Q406X mutation, which eliminates the last
80 amino acids of the protein, was found in two males
with delayed development, macrocephaly, seizures,
ataxia, and absence of language (Meloni et al. 2000).
Females with this same mutation were unaffected, even
with balanced XCI patterns (Meloni et al. 2000).
Many missense mutations have been identified in
males with nonspecific X-linked mental retardation
(MRX). In fact, the observed frequency of MECP2 mu-
tations in a large collection of males with MRX (∼2%)
is almost as high as the frequency of trinucleotide
expansions in the FMR1 gene in this population
(∼3%–4%) (Couvert et al. 2001). The A140V mutation
has been associated with a number of phenotypes: men-
tal retardation; mental retardation with abnormal gait
and speech difficulty; childhood-onset schizophrenia
with loss of language; and a syndrome characterized by
manic-depressive psychosis, pyramidal signs, and macro-
orchidism (Orrico et al. 2000; Couvert et al. 2001; Co-
hen et al. 2002; Klauck et al. 2002). Because males with
these mutations survive into adulthood and females with
the same mutations are unaffected despite balanced XCI
patterns, these types of mutations appear to be less det-
rimental to MeCP2 function than those causing RTT.
Whereas RTT-causing mutations typically lead to either
premature truncation or nonconservative amino acid
changes, the milder mutations are more often conser-
vative amino acid changes or truncations that preserve
a significant portion of the coding region. Given that a
single mutation (e.g., A140V) can have disparate effects
in different families, other genetic factors probably con-
tribute to this phenotypic variability.
MeCP2 Function
MeCP2 binds preferentially to DNA methylated at CpG
sites through an 85–amino acid methyl-CpG–binding
domain (MBD) (amino acids 78–162) (Lewis et al. 1992;
Nan et al. 1993). Once bound to DNA, MeCP2 is
thought to silence transcription of downstream genes by
recruiting corepressor complexes through a 104–amino
acid transcriptional repression domain (TRD) (amino
acids 207–310) (Nan et al. 1997). One complex shown
to associate with MeCP2 is the Sin3A corepressor com-
plex (Jones et al. 1998; Nan et al. 1998). This complex
contains histone deacetylase (HDAC) 1 and HDAC2 and
was originally shown to mediate repression by the DNA-
binding heterodimer, Mad-Max (Laherty et al. 1997).
MeCP2 also interacts with two other corepressors, the
proto-oncoprotein of the Sloan-Kettering virus named
after the Sloan-Kettering Institute (c-Ski) and the nuclear
receptor corepressor (N-CoR) (Kokura et al. 2001). c-
Ski and N-CoR are components of histone deacetylase
complexes that can but do not always function together
(Heinzel et al. 1997; Nomura et al. 1999). It is interesting
that repression by MeCP2 is not completely alleviated
by the histone-deacetylase inhibitor, trichostatin A
(TSA), suggesting that MeCP2 may also repress tran-
scription in an HDAC-independent manner (Jones et al.
1998; Yu et al. 2000). In support of this idea, the TRD
interferes with the assembly of the transcriptional prein-
itiation complex on naked DNA and interacts directly
with transcription factor IIB (TFIIB), a component of
the basal transcriptional machinery (Kaludov and Wolffe
2000).
In addition to the MBD and the TRD, there are two
other domains of MeCP2 associated with specific func-
tions. First, lying within the TRD is the nuclear local-
ization signal (amino acids 255–271), which is sufficient
for transportation of the protein into the nucleus (Nan
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et al. 1996). Second, the last 63 amino acids of MeCP2
have been shown to facilitate binding of the protein to
both naked and nucleosomal DNA (Chandler et al.
1999). Another study, however, showed that this region
decreases binding to methylated DNA but may increase
protein stability (Yusufzai and Wolffe 2000).
Effect of Mutations on MeCP2 Function
Missense mutations identified in the MECP2 gene in
patients with RTT cluster in the MBD and TRD, but
some are found outside these regions and also in the C-
terminus. In vitro studies have demonstrated that many
missense mutations within the MBD (R106W, R111G,
Y123A, I125A, R133C, F155S, and T158M) signifi-
cantly reduce the affinity of MeCP2 for methylated DNA
(Ballestar et al. 2000; Yusufzai and Wolffe 2000; Free
et al. 2001). Consistent with these observations, MeCP2
with the R106W or F155S mutation, when transfected
into cells, is impaired in its ability to localize to hetero-
chromatic domains and to repress transcription of a re-
porter (Kudo et al. 2001). It is interesting that the A140V
and E137G mutants (within the MBD), which cause
milder phenotypes in humans, localize normally to
heterochromatin but have diminished repressive capa-
bility (Kudo et al. 2002). This suggests that amino acids
in the MBD may have roles outside of binding methyl-
CpG sequences or that the heterochromatic localization
assay is not sensitive enough to detect the diminished
binding affinity. As expected, MeCP2 proteins that retain
the MBD but are truncated within the TRD are able to
bind methylated DNA but are impaired in their ability
to repress transcription (Yusufzai and Wolffe 2000). Less
expected is that one missense mutation in the TRD
(R306C) does not reduce repressive activity of MeCP2
in a transfection assay, although it may have stronger
effects in vivo (Yusufzai and Wolffe 2000). Deletions
within the C-terminus of MeCP2, which are common
mutations in classic RTT, significantly decrease protein
stability (Yusufzai and Wolffe 2000).
DNA Methylation
Because the function of MeCP2 is strongly tied to
DNA methylation, an understanding of the role of meth-
ylation is necessary to gain insight into the molecular
basis of RTT. Whereas promoters of cellular “house-
keeping” genes are relatively rich in CpG yet protected
from methylation (Bird et al. 1985), other genes are
methylated in unique ways. Tissue-specific genes are of-
ten methylated in nonexpressing tissues, X-linked genes
are methylated on the inactive X-chromosome, and im-
printed genes are methylated according to their parental
origin. In addition to cellular genes, satellite DNA, re-
troviruses, and transposable elements are highly meth-
ylated (Yoder et al. 1997). Genomewide methylation is
thought to occur early in embryonic development (Lock
et al. 1987; Kafri et al. 1992). In the developing germ-
line, methylation patterns are erased, and a second phase
of methylation establishes imprinting patterns according
to the sex of the embryo (Kafri et al. 1992; Brandeis et
al. 1993). DNA methylation is now known to be ac-
complished by two classes of DNA methyltransferases
(DNMTs). DNMT3a and DNMT3b are partially re-
dundant de novo methyltransferases, which establish the
methylation pattern (Okano et al. 1998, 1999). DNMT1
is a maintenance methyltransferase, which preserves the
methylation pattern through DNA replication by meth-
ylating the newly synthesized DNA strand (Bestor and
Ingram 1983). Demonstrating the essential role of meth-
ylation in gene regulation and development, Dnmt1-de-
ficient mice and mice lacking both Dnmt3a and Dnmt3b
die before embryonic day (E) 11.5 (Li et al. 1992; Okano
et al. 1999). Because MECP2 mutations result in a pri-
marily neurological phenotype, it appears that MeCP2
is essential only for the regulation of a subset of meth-
ylated genes.
MeCP2 Target Genes
MeCP2 has been shown to bind and/or silence a num-
ber of methylated genes, including retroviral, tissue-spe-
cific, and imprinted genes. For example, in cell lines in-
fected with the Moloney murine leukemia virus, MeCP2
associates with the provirus in a methylation-dependent
manner (Lorincz et al. 2001). LINE-1 but not Alu retro-
transposons are also repressed by MeCP2 in transfection
assays (Yu et al. 2001). Genes methylated in a cell- or
tissue-specific manner may also be regulated by MeCP2.
For example, the leukosialin gene, which is differentially
methylated depending on the tissue, is repressed by
MeCP2 in a transfection assay when the promoter is
methylated, although whether MeCP2 binds to this pro-
moter in vivo remains to be determined (Kudo 1998).
In addition, the multidrug resistance gene promoter in
drug-sensitive cells is hypermethylated and bound by
MeCP2, whereas in drug-resistant cells, the promoter is
hypomethylated, transcriptionally active, and relatively
free of MeCP2 (El-Osta and Wolffe 2001; El-Osta et al.
2002). MeCP2 has also been implicated in the regulation
of imprinted genes. For example, MeCP2 binds selec-
tively to the paternal allele of the differentially meth-
ylated domain of the H19 gene (Drewell et al. 2002)
and to the maternal (methylated) allele of the imprinted
U2af1-rs1 gene (Gregory et al. 2001). It is interesting
that several imprinted genes have been implicated in neu-
rological functions, including Ube3a, mutated in An-
gelman syndrome (Kishino et al. 1997; Matsuura et al.
1997), and Peg1, an imprinted gene, which, when de-
leted in mice, causes abnormal maternal behavior and
growth retardation (Lefebvre et al. 1998). Whether any
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of these genes is abnormally expressed in RTT remains
to be determined.
Methyl-CpG–Binding Proteins
Given that methylation is essential for viability in
mice, it is not too surprising that a number of proteins
other than MeCP2 bind to methylated DNA. A group
of proteins, MBD1, MBD2, MBD3, and MBD4, are so
named because they contain a methyl-CpG–binding do-
main similar to that of MeCP2 (Cross et al. 1997; Hen-
drich and Bird 1998). Another protein, Kaiso, which has
homology to the POZ zinc finger family of DNA-binding
transcription factors but does not contain the classical
MBD motif, has also been shown to specifically bind
methylated DNA (Daniel and Reynolds 1999; Prok-
hortchouk et al. 2001). MBD1, MBD2, and MBD4, like
MeCP2, can bind DNA containing only one symmet-
rically methylated CpG site and can localize to centrom-
eric heterochromatin in transfected cells (Hendrich and
Bird 1998; Fujita et al. 1999; Ng et al. 1999). In contrast,
Kaiso requires at least two symmetrically methylated
CpG sites to bind DNA, and MBD3 lacks the ability to
bind methylated DNA in vitro (Hendrich and Bird 1998;
Prokhortchouk et al. 2001).
In addition to sharing the ability to bind methylated
CpG sites, MBD1, MBD2, and Kaiso are similar to
MeCP2 in their ability to repress transcription (Ng et
al. 1999; Boeke et al. 2000; Ng et al. 2000; Prokhortch-
ouk et al. 2001). It is interesting to note that Kaiso has
no sequence homology to the MBD family members, yet
it is able to perform a similar function; thus, the true
number of methyl-CpG–binding transcriptional repres-
sors may be much higher than previously suspected.
Considering the high level of functional similarity within
this group of proteins, it seems likely that there would
be at least partial compensation when one member is
deleted. The primarily neurological phenotype of
MECP2 mutations, however, leads us to hypothesize
that this protein has some function that is specific to
neurons and is not compensated for by other members
of the MBD family.
MeCP2 Expression Pattern
Studies of the expression pattern of MECP2 indicate
that MeCP2 may indeed have a specialized role in neu-
rons. Analysis of the MECP2 mRNA has been compli-
cated by the presence of three alternatively spliced tran-
scripts (1.9 kb, 7.5 kb, and 10 kb) produced by
differential polyadenylation site usage within the 3′-un-
translated region (UTR) (Reichwald et al. 2000). These
transcripts are found at varying levels in most tissues
examined, with no obvious preference for nervous tissue
(D’Esposito et al. 1996; Coy et al. 1999; Reichwald et
al. 2000). The apparent tissue-specificity of the three
MECP2 transcripts and the presence of distinct 3′-UTRs
suggest that the transcripts might have unique roles. To
circumvent the difficulty of interpreting the expression
pattern from multiple transcripts, however, the distri-
bution of the MeCP2 protein has been analyzed. Unlike
the mRNA, the protein is expressed at higher levels in
the brain than in many other tissues (LaSalle et al. 2001;
Shahbazian et al. 2002a). Within the brain, MeCP2 is
present at high levels in most neurons but not in glia
(Akbarian et al. 2001; LaSalle et al. 2001; Shahbazian
et al. 2002a).
MeCP2 levels also vary in a neuron-specific manner
(LaSalle et al. 2001; Shahbazian et al. 2002a). In the
developing cerebral cortex of mouse, human, and non-
human primate embryos, the appearance of MeCP2 cor-
relates with neuronal maturation, with earlier-born neu-
rons expressing MeCP2 before later-born neurons
(Akbarian et al. 2001; Shahbazian et al. 2002a). These
results may partly explain why the brain is most affected
in RTT, why the development of white matter progresses
normally although neuronal development does not, why
certain neuronal populations appear more affected than
others, and why the onset of disease is delayed. Under-
standing the functions of MeCP2 that are specific to
mature neurons will be the next challenge in elucidating
the pathogenesis of RTT.
Mouse Models of RTT
Tools for studying the in vivo role of MeCP2 have
been produced by mutating Mecp2 in mice (table 3).
Male mice with a null mutation inMecp2 display stunted
body and head growth, hypoactivity, hindlimb-clasping,
irregular breathing, and death within 6–10 wk (Chen et
al. 2001; Guy et al. 2001) (table 3). Deletion of Mecp2
in developing neurons results in the same phenotype,
demonstrating that the observed deficiencies in the null
mice are solely a consequence of neuronal dysfunction
and that no overt phenotypes result from MeCP2 dys-
function outside the nervous system, at least within the
lifespan of these mice (Guy et al. 2001). These studies
also showed that MeCP2 is important not only for de-
veloping neurons but also for postmitotic neurons, since
deletion of Mecp2 solely in postmitotic neurons results
in a phenotype that is later and milder than that of the
null allele (Chen et al. 2001). In Mecp2-null mice, con-
comitant loss of Mbd2 does not worsen the phenotype,
suggesting that Mbd2 alone does not compensate for the
loss of MeCP2 (Guy et al. 2001). Truncation of the C-
terminus of MeCP2 in mice leads to a milder phenotype
than the null allele, as revealed by the survival of male
mice (Shahbazian et al. 2002c). These mice display many
features of RTT, including tremors, motor impairments,
hypoactivity, anxiety, seizures, kyphosis, and stereotyp-
ical forepaw motions (table 3). Elevated levels of acet-






HYPOMORPHIC ALLELEaNull Allele Hypomorphic Allele
Age at onset Appear normal for 5 wk Appear normal for 6 wk Appear normal for 6 wk
Head/body size Small head, body size
Involuntary movements Tremors Tremors Tremors
Seizures Seizures
Motor function Motor deficiencies Motor deficiencies




Life span Death at 6–10 wk
Social interactions Anxiety and abnormal social interactions
a These female mice have not been thoroughly characterized.
ylated histone H3 in brain tissue from these mice suggest
that transcriptional alterations may underlie the phe-
notype (Shahbazian et al. 2002c).
Role of DNA Methylation in Neuronal Function
Because MeCP2 may prove to be important for reg-
ulating methylated genes, particularly in neurons, it is
worthwhile considering what is known about the role
of methylation in neuronal function. It has been ques-
tioned for some time why expression levels of theDnmt1
maintenance methyltransferase are high in brain, and,
more specifically, high in neurons, but are undetectable
in glia (Goto et al. 1994). The role of Dnmt1 in neurons
has been studied by conditionally deleting the gene in
mice. Dnmt1 deficiency in neuronal precursors at E9–E10
allows proper development and survival of neurons
through birth but adversely affects neuronal survival after
birth (Fan et al. 2001). In contrast, deletion of Dnmt1
in postmitotic neurons does not affect neuronal survival
or methylation of retroviral DNA (Fan et al. 2001). The
questions that remain are whether Dnmt1 deficiency in
postmitotic neurons leads to changes in the methylation
of unique sequences and whether neuronal function is
perturbed.
Changes in gene expression mediated by DNA meth-
ylation are thought to be important for neuronal mat-
uration. Studies of a model system of neuronal differ-
entiation—PC12 pheochromocytoma cells induced to
differentiate with nerve growth factor (NGF)—have
shown that gene methylation is required for neurite out-
growth (Persengiev and Kilpatrick 1996). Consistent
with this finding, expression levels of several genes are
reduced during differentiation of PC12 cells but only in
the presence of DNA methyltransferase activity (Persen-
giev and Kilpatrick 1997). Substantiating the link be-
tween neuronal differentiation and chromatin modifi-
cations is the observation that the histone deacetylase
inhibitor, TSA, also inhibits NGF-induced neurite out-
growth of PC12 cells (Futamura et al. 1995). In vivo
evidence supports the role of epigenetic modifications in
neuronal development, as several neuronal gene pro-
moters have been found to undergo developmental
changes in methylation. For example, the methylation
pattern of the neuronal-specific gene Stac changes during
mouse development (Suzuki et al. 1996). In addition,
GFAP becomes methylated in neurons but not glia of
the rat brain (Barresi et al. 1999). Because both meth-
ylation and histone deacetylation appear to be involved
in neurite extension of PC12 cells and because dendrites
appear to be underdeveloped in RTT brains, it is con-
ceivable that MeCP2 plays a role in mediating the chro-
matin modifications necessary for dendritic outgrowth.
In addition to changes in neuronal chromatin struc-
ture that may occur during development, it is worth
considering whether there are changes in chromatin
structure in fully differentiated neurons. The fact that
Dnmt3a/ mice are normal at birth but show impaired
growth and die at 4 wk of age (Okano et al. 1999)
suggests that de novo methylation by this enzyme is ei-
ther important during the embryonic stage for postnatal
survival or that it is important after birth. Because
Dnmt3a is expressed only in a few adult tissues, one of
which is the brain (Okano et al. 1998), it is possible that
de novo methylation is important in the brain after birth.
There is already some evidence to suggest this, since
DNA methylation levels increase in neurons after cere-
bral ischemia induced by temporary blockage of the ce-
rebral artery (Endres et al. 2000). Thus, in postmitotic
neurons, neuronal methylation patterns (and, presum-
ably, gene expression) are regulated in response to at
least one environmental factor. This leads to the question
of whether methylation plays a role in neuronal re-
sponses to other types of stress or experiences.
The fact that both Mbd2 and Mecp2 mutant mice
show primarily or solely neuronal phenotypes that man-
ifest after birth may suggest that these MBD proteins
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are specialized to mediate methylation events that occur
in mature neurons. Mecp2 mutant mice display abnor-
mal responses to a novel environment; they are hy-
poactive and more anxious than wild-type mice, further
indicating that methylation might be regulated in re-
sponse to the environment (Shahbazian et al. 2002c). It
is noteworthy that a light pulse applied to mice induces
phosphorylation of serine 10 on histone H3, specifically
in neurons of the hypothalamic suprachiasmatic nucleus
that function as a circadian clock (Crosio et al. 2000).
Serine 10 phosphorylation of histone H3 is known to
enhance acetylation of the nearby lysine 14 (Cheung et
al. 2000). These results suggest that environmental sig-
nals can, indeed, dynamically affect chromatin architec-
ture in neurons.
To understand the molecular basis of RTT and the
role of epigenetics in neuronal function, it is essential to
identify genes that are targets of MeCP2 repression and
determine whether their expression is altered in patients
or mouse models. Gene-expression analysis of postmor-
tem RTT brain tissue has revealed reduced expression
of a number of neuronal-specific genes and upregulation
of some glial-specific genes, although these changes
likely reflect secondary changes that occur long after the
initial insult (Colantuoni et al. 2001). Now that mouse
models of RTT are available, it will be easier to dissect
the primary changes in gene expression and neuronal
function that underlie the RTT phenotype.
Concluding Remarks
It is becoming evident that MeCP2, a protein originally
thought of as a global transcriptional repressor, is ac-
tually specialized for a function in neurons of the central
nervous system. It is remarkable that mouse models have
reproduced virtually every aspect of RTT, including the
highly specialized hand-wringing behaviors, suggesting
that the pathways leading from dysfunctional MeCP2
to each of these features are conserved between humans
and mice. Gene expression analyses in these mouse mod-
els may help elucidate the neuronal-specific functions of
MeCP2 that are misregulated in RTT. To understand the
basis for the selective function of MeCP2, it may be
worthwhile to search for additional interacting factors.
Given that, in humans, the phenotypic outcome of
MECP2 truncation mutations depends on the position
of the truncation, different regions of MeCP2 may in-
teract with particular proteins or complexes. Uncovering
the molecular alterations that lead to RTT will not only
provide insight into the disease pathogenesis but may
also shed light on the normal role of epigenetic modi-
fications in the function of developing and mature
neurons.
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for RTT [MIM 312750] and
MeCP2 [MIM 300005])
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